Jean Bennett
CIK: 0001872219
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Opus Genetics to Present at Euretina 2026. Opus Genetics announced it will present data at the Euretina 2026 conference. This event is relevant as it provides a platform for the company to share scientific updates on its gene therapy programs. The stock currently trades below the average analyst target price, with a 52-week range spanning from $1.32 to $7.07.
Transaction History
| RGNX | ▲ Buy | Grant | 9,807 | $0 | 5/29/2026 | View on chart |
| IRD | ▲ Buy | Grant | 24,367 | $0 | 4/20/2026 | View on chart |
| IRD | ▲ Buy | Grant | 21,127 | — | 1/1/2026 | View on chart |
| RGNX | ▲ Buy | Grant | 7,768 | $0 | 5/30/2025 | View on chart |
| IRD | ▲ Buy | Grant | 79,504 | $0 | 4/30/2025 | View on chart |
| IRD | ▲ Buy | Grant | 34,021 | — | 1/2/2025 | View on chart |
| IRD | ▲ Buy | Grant | 100,000 | $0 | 10/22/2024 | View on chart |
| RGNX | ▲ Buy | Grant | 4,790 | $0 | 5/31/2024 | View on chart |
| RGNX | ▲ Buy | Grant | 3,486 | $0 | 6/2/2023 | View on chart |
| RGNX | ▲ Buy | Grant | 3,010 | $0 | 6/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
RGNX Reports Positive 3-Year Data and Settles Patent Litigation
RGNX presented three‑year data showing most NPDR patients improved by more than two steps on the DRSS, with no vision‑threatening events. The company also shared durability results for Surabgene Lomparvovec at the Retina Society meeting. In addition, RGNX settled all Elevidys patent disputes with Sarepta for $39 million and agreed to drop further litigation. These developments highlight progress in both clinical and legal fronts.
RGNX Reports Positive 3-Year Data and Settles Patent Litigation. RGNX presented three‑year data showing most NPDR patients improved by more than two steps on the DRSS, with no vision‑threatening events. The company also shared durability results for Surabgene Lomparvovec at the Retina Society meeting. In addition, RGNX settled all Elevidys patent disputes with Sarepta for $39 million and agreed to drop further litigation. These developments highlight progress in both clinical and legal fronts.